Critical Alert
Wisconsin Pharmacal Company Recalls MG217 Multi-Symptom Treatment Cream & Skin Protectant
This is a Class I recall — the most serious type. There is a reasonable probability of serious health consequences or death.
Source: FDA
CriticalRecall #D-0553-2026Drug / Pharmaceutical
Wisconsin Pharmacal Company Recalls MG217 Multi-Symptom Treatment Cream & Skin Protectant
Wisconsin Pharmacal Company · Class I — Most Serious
Product Description
MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%), NET WT 6 oz (170 g), Manufactured by: Pharmacal 1 Pharmacal Way, P.O. Box 198, Jackson, WI 53037.
Reason for Recall
Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus.
FDA Classification
Class I — Most Serious
A situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.
Distribution
USA Nationwide and Bahamas
Remedy
Consumers should stop using this product. Contact the recalling firm for further instructions regarding this product.
411 Press Analysis
Wisconsin Pharmacal Company is recalling a pharmaceutical product classified as Class I by the FDA — the highest risk level. The recall was initiated on April 24, 2026 affecting 690 tubes. Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus. It was distributed in USA Nationwide and Bahamas. Consumers and healthcare professionals should exercise caution and discontinue use of the recalled product. Contact the recalling firm directly for return or disposal instructions.
Sources: FDA openFDA Enforcement Database
This recall appears in: Drug & Medical Product Contamination.